Overview

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Status:
Completed
Trial end date:
2019-06-20
Target enrollment:
Participant gender:
Summary
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combination with vaccine therapies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NewLink Genetics Corporation
Treatments:
Bevacizumab
Dacarbazine
Temozolomide
Tryptophan